ArriVent BioPharma, Inc.
AVBP evidence brief
What we can confirm
- Market Cap:
- $1.47B
What it means
What to watch
Prepared research question
What matters most for AVBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVBP
ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on developing differentiated cancer therapies, with lead candidate firmonertinib for EGFR-mutant non-small cell lung cancer and a pipeline of antibody-drug conjugates including ARR-217 and ARR-002.
Key risk: No revenue from sales
Market Cap
$1.47B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for ArriVent BioPharma, Inc..
ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on developing differentiated cancer therapies, with lead candidate firmonertinib for EGFR-mutant non-small cell lung cancer and a pipeline of antibody-drug conjugates including ARR-217 and ARR-002.
- Lead product candidate firmonertinib is in a global pivotal Phase 3 trial for first-line EGFR exon 20 insertion mutant NSCLC, with topline data expected in the second half of 2026 [news · 2026-08-12].
- Cash and investments totaled $373.1 million as of June 30, 2026, expected to fund operations into 2028 [news · 2026-08-12].
- Net loss of $49.9M reported for the period ended June 30, 2026 [latest reported financials].
- ADC pipeline includes ARR-217 (Phase 1b dose optimization for gastrointestinal malignancies) and ARR-002 (MUC16/NaPi2b tetravalent ADC, first patient dosing expected Q3 2026) [news · 2026-08-12].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-12].
What works
- Strong cash position of $373.1 million as of June 30, 2026, providing a runway into 2028 [news · 2026-08-12].
- Multiple clinical-stage programs: firmonertinib in Phase 3, ARR-217 in Phase 1b, and ARR-002 entering Phase 1, diversifying pipeline risk [news · 2026-08-12].
- Partnership with Lepu Biopharm for ARR-217 development, sharing costs and expertise [sec_mda · as of 2026-08-12].
- FDA clearance of IND for ARR-002, a potential first-in-class dual-targeting ADC, indicating regulatory progress [sec_mda · as of 2026-08-12].
What to weigh
- No approved products and no revenue from product sales to date, relying entirely on external funding [sec_mda · as of 2026-08-12].
- Net loss of $49.9M for the six months ended June 30, 2026, reflecting high R&D spending without offsetting revenue [latest reported financials].
- Competitive pressure in EGFR exon 20 insertion NSCLC: sunvozertinib (Dizal/AstraZeneca) already approved and submitted for first-line use [sec_mda · as of 2026-08-12].
- Clinical-stage risks: interim results may not be indicative of final outcomes, and capital could be depleted sooner than expected if assumptions prove wrong [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Lead candidate firmonertinib Phase 3 data expected 2H 2026
“Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026”
News · August 12, 2026
Cash and investments of $373.1 million as of June 30, 2026
“Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028”
News · August 12, 2026
No approved products and no revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sales or otherwise.”
SEC MD&A · August 12, 2026
ARR-002 IND cleared by FDA in May 2026
“In May 2026 we announced clearance of a U.S. investigational new drug ("IND") application by the FDA for ARR-002”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2022-06-30 · Phase 1 start for furmonertinib (firmonertinib) in advanced/metastatic NSCLC with EGFR/HER2 mutations — Initiated dose escalation and expansion study evaluating safety, pharmacokinetics, and antitumor activity.
- 2023-06-01 · Phase 3 start for firmonertinib (FURVENT) in first-line EGFR exon 20 insertion NSCLC — Global randomized open-label study comparing firmonertinib to platinum-based chemotherapy.
- 2025-05-28 · Phase 3 start for firmonertinib in first-line PACC mutant NSCLC — Enrollment underway for global pivotal study in patients with PACC mutations.
Risks & what to watch (3)›
Key risks
- No revenue from sales — Company has no approved products and has not generated any product revenue, relying solely on external funding [sec_mda · as of 2026-08-12].
- Clinical trial uncertainty — Interim results may not be indicative of final outcomes; capital could be depleted sooner than expected [sec_mda · as of 2026-08-12].
- Competitive pressure in EGFR exon 20 — Sunvozertinib (Dizal/AstraZeneca) already FDA-approved and submitted for first-line use, creating a crowded field [sec_mda · as of 2026-08-12].
What to watch
- Topline Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion NSCLC, expected 2H 2026 [news · 2026-08-12].
- First patient dosing of ARR-002 (MUC16/NaPi2b ADC) expected Q3 2026 [news · 2026-08-12].
- Progress of ARR-217 Phase 1b dose optimization for gastrointestinal malignancies [news · 2026-08-12].
- Cash runway updates: $373.1M as of June 30, 2026 expected to fund operations into 2028 [news · 2026-08-12].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run ArriVent BioPharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ArriVent BioPharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 16.3%
- Days to cover
- 14.0
- Shares short
- 7,109,751
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ArriVent BioPharma, Inc.?
ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on developing differentiated cancer therapies, with lead candidate firmonertinib for EGFR-mutant non-small cell lung cancer and a pipeline of antibody-drug conjugates including ARR-217 and ARR-002.
Who is the CEO of ArriVent BioPharma, Inc.?
Dr. Zhengbin Yao Ph.D. is the chief executive officer of ArriVent BioPharma, Inc. (AVBP).
Where is ArriVent BioPharma, Inc. headquartered?
ArriVent BioPharma, Inc. (AVBP) is headquartered in Newtown Square, PA, United States.
What therapeutic areas does ArriVent BioPharma, Inc. focus on?
ArriVent BioPharma, Inc. develops therapies across Oncology, Immunology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.